These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 4904268)

  • 21. Prolonged survival of cardiac allografts in a closely-bred dog colony.
    Boyd AD; Ferrebee JW; Cannon FD; Gherunpong C; Lower RR; Spencer FC; Rapaport FT
    Surg Forum; 1970; 21():188-90. PubMed ID: 4936966
    [No Abstract]   [Full Text] [Related]  

  • 22. [Radiologic and microscopic comparative study of the reaction of homologous pulmonary transplant rejection in untreated dogs].
    Grosjean O; Simar L; Leroux G; de Leval M; Otte H; Honore D
    Acta Chir Belg; 1969 Nov; 68(8):577-85. PubMed ID: 4928776
    [No Abstract]   [Full Text] [Related]  

  • 23. Heart-reactive antibody: an index of cardiac rejection in human heart transplantation.
    Ellis RJ; Lillehei CW; Fischetti VA; Zabriskie JB
    Circulation; 1970 May; 41(5 Suppl):II91-7. PubMed ID: 4952946
    [No Abstract]   [Full Text] [Related]  

  • 24. Decay-accelerating factor expression may provide immunoprotection against antibody-mediated cardiac allograft rejection.
    González-Stawinski GV; Tan CD; Smedira NG; Starling RC; Rodríguez ER
    J Heart Lung Transplant; 2008 Apr; 27(4):357-61. PubMed ID: 18374870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytotoxic antibodies following human renal transplantation.
    Cochrum KC; Kountz SL
    Surg Forum; 1969; 20():302-4. PubMed ID: 4910605
    [No Abstract]   [Full Text] [Related]  

  • 26. Peptides derived from alpha-helices of allogeneic class I major histocompatibility complex antigens are potent inducers of CD4+ and CD8+ T cell and B cell responses after cardiac allograft rejection.
    Shirwan H; Leamer M; Wang HK; Makowka L; Cramer DV
    Transplantation; 1995 Feb; 59(3):401-10. PubMed ID: 7871571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Occurrence of circulating heart-reactive antibodies in a population of cardiac transplant recipients. Correlation with cardiac rejection and subsequent course.
    Anderson JL; Fowles RE; Stinson EB; Yuge C; Bieber CP; Harrison DC
    Circulation; 1979 Sep; 60(3):629-37. PubMed ID: 378458
    [No Abstract]   [Full Text] [Related]  

  • 28. [On the specificity of antilymphocyte antibodies. (Experimental research in several animal species)].
    Bigliani S; Canino V; Mensi E
    Minerva Nipiol; 1968; 18():Suppl 6:239+. PubMed ID: 4910412
    [No Abstract]   [Full Text] [Related]  

  • 29. [Experimental studies on donor heart preservation for cardiac transplantation].
    Ueto T; Todo K; Hasegawa T; Kazui T; Tomita F
    Kyobu Geka; 1970 Oct; 23(10):732-40. PubMed ID: 4918047
    [No Abstract]   [Full Text] [Related]  

  • 30. Cytotoxic antibody after antigen pretreatment: enhancement of renal allografts.
    Holl-Allen RT; Scharli A; Rippin A; Busch GJ; Simonian SJ; Wilson RE
    Surg Forum; 1969; 20():276-8. PubMed ID: 4910594
    [No Abstract]   [Full Text] [Related]  

  • 31. Specific suppression of renal allograft rejection by treatment with antigen and antibody.
    Stuart FP; Fitch FW; Rowley DA
    Transplant Proc; 1970 Dec; 2(4):483-8. PubMed ID: 4939695
    [No Abstract]   [Full Text] [Related]  

  • 32. [Tissue incompatibility on a mother-fetus model].
    Viazov OE; Verbitskiĭ MSh
    Usp Sovrem Biol; 1968; 66(3):424-38. PubMed ID: 4916818
    [No Abstract]   [Full Text] [Related]  

  • 33. Prevention of bone marrow and cardiac graft rejection in an H-2 haplotype disparate mouse combination by an anti-LFA-1 antibody.
    Cavazzana-Calvo M; Sarnacki S; Haddad E; De Coene C; Calise D; Yvon E; Cerf-Bensussan N; Fischer A
    Transplantation; 1995 Jun; 59(11):1576-82. PubMed ID: 7778173
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of platelet aggregation in canine renal allotransplants with serum cytotoxic antibody following treatment with azathioprine.
    Lowenhaupt RW; Nathan P; Menefee MG
    Transplant Proc; 1971 Mar; 3(1):453-6. PubMed ID: 4937917
    [No Abstract]   [Full Text] [Related]  

  • 35. Mechanisms of human cardiac allograft rejection: absence of co-stimulatory molecules and cell adhesion molecules on major histocompatibility complex class I/II+ human cardiac myocytes does not induce anergy.
    Sundstrom JB; Mayne A; Kanter K; Herskowitz A; Ansari AA
    Transplant Proc; 1995 Feb; 27(1):1310-3. PubMed ID: 7878895
    [No Abstract]   [Full Text] [Related]  

  • 36. Heart graft arteriosclerosis.
    Kosek JC; Bieber C; Lower RR
    Transplant Proc; 1971 Mar; 3(1):512-4. PubMed ID: 4937928
    [No Abstract]   [Full Text] [Related]  

  • 37. Characterization of mononuclear cell infiltrates in human cardiac allografts.
    Marboe CC; Schierman SW; Rose E; Reemtsma K; Fenoglio JJ
    Transplant Proc; 1984 Dec; 16(6):1598-9. PubMed ID: 6390870
    [No Abstract]   [Full Text] [Related]  

  • 38. Chronic rejection of murine cardiac allografts discordant at the H13 minor histocompatibility antigen correlates with the generation of the H13-specific CD8+ cytotoxic T cells.
    Yang J; Jaramillo A; Liu W; Olack B; Yoshimura Y; Joyce S; Kaleem Z; Mohanakumar T
    Transplantation; 2003 Jul; 76(1):84-91. PubMed ID: 12865791
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The efficiency of sheep antidog antilymphocyte serum (SADALS) in the prolongation of canine heart allografts.
    Halpern B; Cachera JP; Lacombe M; Hathaway A; Crepin Y; Hung BM; Lacassagne JP; Leandri J; Laurent D; Dubost C; de Mendoza M
    Transplant Proc; 1969 Mar; 1(1):467-9. PubMed ID: 4944261
    [No Abstract]   [Full Text] [Related]  

  • 40. The use of human F(ab') 2 fragments as blocking agents in the mixed lymphocyte reaction.
    Hornung MO; Layne E; McDonald JC
    J Immunol; 1971 Oct; 107(4):979-84. PubMed ID: 4999263
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.